Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961630 · ClinicalTrials.gov registry record · Early Phase 1
Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction
A Early Phase 1 study of Myocardial Injury After Non-cardiac Surgery, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06961630: Recruiting Early Phase 1 study of Myocardial Injury After Non-cardiac Surgery, sponsored by NYU Langone Health.
NCT06961630 is a Early Phase 1 study of Myocardial Injury After Non-cardiac Surgery that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06961630, a Early Phase 1 study of Myocardial Injury After Non-cardiac Surgery, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study drug adherence, and optimize study design (entry criteria, study endpoints, sample size calculation, site selection) and recruitment strategies for the future multicenter randomized clinical trial studying biomarker-based care in post-operative patients at elevated cardiovascular (CV) risk.
Primary Outcome
Treatment adherence will be assessed by pill count and patient self report.
Conditions Studied
Interventions
- DRUG Atorvastatin
- DRUG Rivaroxaban
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
What NCT06961630 shows while recruiting
NCT06961630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Myocardial Injury After Non-cardiac Surgery appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin is the first listed.
NCT06961630 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06961630 about?
NCT06961630 is a clinical study titled "Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction". The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study ...
What is the current status of trial NCT06961630?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-10-07. Estimated completion is 2027-03-31.
What conditions does trial NCT06961630 study?
This clinical trial studies the following conditions: Myocardial Injury After Non-cardiac Surgery.
What interventions are being tested in trial NCT06961630?
The interventions under investigation include: Atorvastatin (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT06961630?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961630 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Injury After Non-cardiac Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06961630's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,468 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI